×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:ACRX

AcelRx Pharmaceuticals News Headlines

$0.18
-0.02 (-10.00%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.18
$0.21
50-Day Range
$0.18
$0.29
52-Week Range
$0.16
$1.55
Volume
933,271 shs
Average Volume
1.30 million shs
Market Capitalization
$26.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Get AcelRx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.

ACRX Media Mentions By Week

ACRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ACRX
News Sentiment

0.00

0.39

Average
Medical
News Sentiment

ACRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ACRX Articles
This Week

1

1

ACRX Articles
Average Week



ACRX Stock News Headlines Today

SourceHeadline
MarketBeat logoAcelRx Pharmaceuticals (NASDAQ:ACRX) Now Covered by Analysts at StockNews.com
americanbankingnews.com - June 23 at 3:12 AM
MarketBeat logoAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Short Interest Update
americanbankingnews.com - June 15 at 1:08 AM
MarketBeat logoAcelRx Pharmaceuticals (NASDAQ:ACRX) Receives New Coverage from Analysts at StockNews.com
americanbankingnews.com - June 14 at 1:26 AM
MarketBeat logoResearch Analysts Issue Forecasts for AcelRx Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:ACRX)
americanbankingnews.com - June 10 at 2:18 AM
MarketBeat logoAcelRx Pharmaceuticals (NASDAQ:ACRX) Research Coverage Started at StockNews.com
americanbankingnews.com - June 6 at 1:16 AM
finance.yahoo.com logoAcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®
finance.yahoo.com - May 19 at 4:33 PM
finance.yahoo.com logoWhy AcelRx Pharma Shares Are Trading Higher Today?
finance.yahoo.com - May 19 at 4:33 PM
seekingalpha.com logoAcelRx Pharmaceuticals, Inc.'s (ACRX) CEO Vincent Angotti on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 18 at 10:56 AM
seekingalpha.com logoAcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 16 at 8:55 PM
finance.yahoo.com logoAcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - May 16 at 7:45 AM
finance.yahoo.com logoAcutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 13 at 12:50 AM
finance.yahoo.com logoAcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia
finance.yahoo.com - May 10 at 1:29 PM
finance.yahoo.com logoAcelRx Hosting Key Opinion Leader Webinar on Niyad™ Nafamostat Program
finance.yahoo.com - April 27 at 9:36 AM
finance.yahoo.com logoAcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022
finance.yahoo.com - April 21 at 12:13 PM
finance.yahoo.com logoAcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures
finance.yahoo.com - March 31 at 8:48 PM
finance.yahoo.com logoAcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit
finance.yahoo.com - March 29 at 6:51 PM
seekingalpha.com logoAcelRx stock falls 15% after HC Wainwright downgrade on 'disappointing quarter'
seekingalpha.com - March 14 at 12:52 PM
seekingalpha.com logoAcelRx stock falls 18% following Q4 results
seekingalpha.com - March 11 at 11:08 AM
markets.businessinsider.com logoHere's what Wall Street expects from AcelRx Pharmaceuticals's earnings report
markets.businessinsider.com - March 11 at 6:07 AM
finance.yahoo.com logoAcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
finance.yahoo.com - March 10 at 7:25 PM
finance.yahoo.com logoAcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates
finance.yahoo.com - March 10 at 7:25 PM
seekingalpha.com logoAcelRx Pharmaceuticals Q4 2021 Earnings Preview
seekingalpha.com - March 9 at 11:18 PM
finance.yahoo.com logoAcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022
finance.yahoo.com - March 3 at 6:56 PM
seekingalpha.com logoAcelRx announces data on pain drug sufentanil sublingual for use in awake plastic surgery
seekingalpha.com - February 1 at 5:18 PM
finance.yahoo.com logoAcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures
finance.yahoo.com - February 1 at 12:17 PM
finance.yahoo.com logoWhen Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Breakeven?
finance.yahoo.com - January 31 at 9:14 AM
finance.yahoo.com logoAcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures
finance.yahoo.com - January 27 at 1:18 PM
finance.yahoo.com logoAcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery
finance.yahoo.com - January 12 at 8:46 AM
finance.yahoo.com logoAcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics
finance.yahoo.com - January 10 at 9:10 AM
finance.yahoo.com logoAcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery
finance.yahoo.com - December 15 at 1:24 PM
nasdaq.com logoAcelrx Pharmaceuticals Inc Shares Approach 52-Week Low - Market Mover
nasdaq.com - November 27 at 1:15 AM
finance.yahoo.com logoAcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors
finance.yahoo.com - November 23 at 6:34 PM
benzinga.com logoAcelRx Pharmaceuticals Earnings Perspective: Return On Capital Employed
benzinga.com - November 15 at 4:58 PM
nasdaq.com logoAcelRx Pharma Posts Narrower Loss In Q3; To Acquire Lowell Therapeutics
nasdaq.com - November 15 at 6:57 AM
finance.yahoo.com logoAcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results
finance.yahoo.com - November 15 at 6:57 AM
finance.yahoo.com logoAcelRx Announces $14 Million Registered Direct Common Stock and Warrant Offering
finance.yahoo.com - November 15 at 6:57 AM
benzinga.com logoAcelRx Pharmaceuticals's Earnings: A Preview
benzinga.com - November 12 at 1:30 PM
finance.yahoo.com logoAcelRx to Host Third Quarter 2021 Financial Results Call and Webcast on November 15, 2021
finance.yahoo.com - November 10 at 12:32 PM
finance.yahoo.com logoInvestors in AcelRx Pharmaceuticals (NASDAQ:ACRX) have unfortunately lost 80% over the last three years
finance.yahoo.com - November 2 at 7:00 AM
finance.yahoo.com logoInvestor Network: AcelRx Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - October 26 at 10:46 AM
benzinga.com logoHow Bad Are AcelRx Pharmaceuticals's Earnings? | Return On Capital Employed
benzinga.com - October 4 at 8:49 PM
benzinga.com logoHow Bad Are AcelRx Pharmaceuticals's Earnings? | Return On Capital Employed
benzinga.com - October 4 at 8:49 PM
finance.yahoo.com logoAdamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
finance.yahoo.com - October 4 at 10:22 AM
finance.yahoo.com logoAcelRx Pharmaceuticals to Participate in Two September Investor Conferences
finance.yahoo.com - September 18 at 9:33 AM
nasdaq.com logoAcelRx Pharmaceuticals, Inc. Common Stock (ACRX)
nasdaq.com - September 8 at 11:04 PM
finance.yahoo.com logoPresentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event
finance.yahoo.com - August 26 at 9:12 AM
finance.yahoo.com logoMoore Kuehn, PLLC Encourages Investors of ACRX to Contact Law Firm
finance.yahoo.com - August 12 at 6:09 PM
finance.yahoo.com logoAcelRx to Host Second Quarter 2021 Financial Results Call and Webcast on August 16, 2021
finance.yahoo.com - August 9 at 1:01 PM
finance.yahoo.com logoACRX Final Deadline Today: Rosen, Trusted National Trial Counsel, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX
finance.yahoo.com - August 9 at 1:01 PM
finance.yahoo.com logoACRX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: August 9, 2021
finance.yahoo.com - August 9 at 1:01 PM
Get AcelRx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:ACRX) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.